Urologix Finds New CEO Among Executive Ranks

In early December the CEO of benign prostatic hyperplasia (BPH) technology company Urologix Inc., Stryker Warren, retired. Chief Operating Officer (COO) Greg Fluet stepped in to serve as interim CEO. The board of directors was so impressed he has now been instated as permanent CEO and elected to a place on the board effective immediately.

“The board has complete confidence that Greg is the right person to lead Urologix,” said Mitchell Dann, chairman of the board. “Greg has consistently demonstrated his strong leadership ability, extensive understanding of the healthcare industry, and sound judgment throughout his four years at Urologix. His transition to interim CEO was seamless and he is already making significant advancements within the company.”

Fluet joined Urologix as executive vice president and COO in July 2008. As COO, Fluet was responsible for all of the company’s operations, global distribution and business development. He was instrumental in the structuring of the 2011 Medtronic agreement for distribution rights to the Prostiva RF (radio frequency) therapy product line. This agreement has allowed Urologix to gain market leadership within benign prostatic hyperplasia in-office treatments and opened up significant market development opportunities. Prior to joining Urologix, Fluet was an associate at Sapient Capital Management LLC, a venture capital firm focused on early stage healthcare investing. The fund is focused primarily on minimally invasive therapeutic medical devices. Fluet graduated from Stanford University with a bachelor of science degree in mechanical engineering.

“BPH is one of the most common diseases faced by men over the age of 50 and these patients deserve to have safe, effective, durable treatment options that don’t require chronic medication or invasive procedures,” Mr. Fluet said. “I am excited and privileged to have the opportunity to lead Urologix at this significant junction in our business as we continue our mission to improve patient’s lives and realize the full-potential of our in-office procedures.”

Based in Minneapolis, Minn., Urologix makes minimally invasive medical products for the treatment of obstruction and symptoms due to BPH.